Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing re... (apacityutilization in the semi-solids se...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship

Date:9/5/2007

apacity utilization in the semi-solids section of our non-sterile operations. The confidence shown in DRAXIS demonstrates our ability to deliver top quality, market leading products in a highly regulated industry, which supports our efforts to build shareholder value."

Manufacturing Site Transfer Activities

The process of transferring these products to DRAXIS Pharma and validating manufacturing procedures for each new product was initiated in late 2006 and will continue through 2007 and 2008. Improvements to the existing semi-solid manufacturing facilities were undertaken during the recent regular shutdown of operations for preventative maintenance during June and July of 2007. Some compounding rooms were enlarged and supplied with required services to accommodate new equipment and additional floor space was created through the construction of a new mezzanine within the existing DRAXIS facility. Capital costs for facility improvements and new equipment specific to this contract will be recovered through a financing agreement.

Commercial production of the products is scheduled to start as soon as late 2008 and ramp up to achieve near full utilization of existing capacity for non-sterile semi-solid products by mid-2009. The contract will result in the creation of approximately 80 to 100 new positions at DRAXIS operations in the Montreal area.

Additional DRAXIS Facility

With the signing of this contract, a second DRAXIS facility in the Montreal area will be required in order to meet increased logistics and secondary packaging activities. This is due to the large number and wide range of finished product formats represented by this new business. All products will be formulated and filled in the existing facility in Kirkland, Quebec. The new secondary facility will be used for operations such as labeling, assembling different product configurations for different markets, cartoning, shipping etc.

This new facility is expected to open du
'/>"/>

SOURCE DRAXIS Health Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Poor health care in Russia maybe causing Decline in its Population
2. Startling Expose – Physicians Often Have No Regular Source Of Health Car
3. Debate Rages over firing of HIV infected health care workers
4. Want a Healthy brew? Have some Tea!
5. Patient’s perception of health status helps in better recover
6. Antioxidants protect health tissue in people undergoing radiation therapy.
7. Sexual abuse affect health for a lifetime
8. Smoking a greater risk than HIV? Yes say health experts!!!!
9. Healthcare sector is now a multi billion-dollar industry in India
10. Exclusive breast-feeding advised for six months in infants recommends World Health Organization
11. How much can exercise improve health?

Post Your Comments:

Breaking Medicine News(10 mins):Health News:The Country's Largest Cooking Magazine Announces The Comfort Food Diet Cookbook 2 Health News:The Country's Largest Cooking Magazine Announces The Comfort Food Diet Cookbook 3 Health News:Drug shows positive responses, low side-effects in multiple myeloma 2 Health News:Minneapolis Dentists, Shamblott Family Dentistry, Ease the Pain and Cost of Emergency Dental Procedures 2 Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 2 Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 3

[0] Self-Help for the Elderly and the Congress of California Seniors to Announce Expansion of Partnership With Verizon on Dec. 8 to Raise Awareness of Elder Abuse [0] The Country's Largest Cooking Magazine Announces The Comfort Food Diet Cookbook [0] Drug shows positive responses, low side-effects in multiple myeloma [0] Minneapolis Dentists, Shamblott Family Dentistry, Ease the Pain and Cost of Emergency Dental Procedures [0] New Blood Thinner Could Replace Warfarin to Fight Venous Clots

So Many Nursing Scrubs, So Many Decisions: blue sky scrubs Offers Tips on How to Find That Perfect Set of Medical Scrubs BioMed Realty Trust Reports Fourth Quarter and Full-Year 2008 Financial Results Boys and Girls Clubs of Central Oregon Get $10K Regence Grant 2008 AAAS Newcomb Cleveland Prize recognizes science paper on limb regeneration in newts Long and Lovely Lashes by LATISSE(TM) Now Available Through Plastic Surgery Services of Fredericksburg Tuba Spells Trouble for Young Musician

Breaking Medicine Technology:VidaySalud.com(TM) Reaches 1,000,000 Page Views In its First Six Months of Operation 2 Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2 Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3 HealthSport, Inc. Closes Stock Purchase Agreement With SMI Manufacturing - Receives $2.5 Million 2 HealthSport, Inc. Closes Stock Purchase Agreement With SMI Manufacturing - Receives $2.5 Million 3 AMERIGROUP Corporation Names Two New Executives 58138 1 AMERIGROUP Corporation Names Two New Executives 58138 2 AMERIGROUP Corporation Names Two New Executives 58138 3 Bubble Trouble Team Hits the Lab for Good Hygiene 58133 1 Bubble Trouble Team Hits the Lab for Good Hygiene 58133 2 Bubble Trouble Team Hits the Lab for Good Hygiene 58133 3 Bubble Trouble Team Hits the Lab for Good Hygiene 58133 4 Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31 2009 14227 1 Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31 2009 14227 2 Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31 2009 14227 3

[0] VidaySalud.com(TM) Reaches 1,000,000 Page Views In its First Six Months of Operation [0] Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day [0] HealthSport, Inc. Closes Stock Purchase Agreement With SMI Manufacturing - Receives $2.5 Million

Other Medicine Technology:New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel 2 New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel 3 New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel 4 New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel 5 Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 2 Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 3 Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 4 Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 5 Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 6 Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 7

New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab

Medicine Products:

IDI-MRSA Test X7000 Lightsource VP1500 Digital Documentation System Linvatec Single CCD Camera Head

Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing re...(apacityutilization in the semi-solids se...),Health